Therapy Watch expands oncology and IBD portfolios
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the US.
CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both first-line and later-line patients, resulting in over 2000 patient record forms (PRFs).
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal Cell Carcinoma (RCC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).
In Autoimmune, the Therapy Watch Inflammatory Bowel Disease (IBD) study which is currently run in Europe and the US will expand into Canada and East Asia with the launch of a new quarterly tracker in Japan. The study which will involve a panel of Gastroenterologists reporting on patients with Ulcerative Colitis (UC) and Crohn’s Disease (CD), will result in over 2100 PRFs over the course of the year for Ulcerative Colitis and 2100 for Crohn’s Disease. Data can be purchased for each indication together or separately.
Therapy Watch is a syndicated market tracking tool that provides marketing teams, brand managers and market researchers with strategic and tactical market information. Run entirely online to ensure speed, quality and up-to-date access to the very latest market data, Therapy Watch offers a clear advantage by putting you in closer contact with your market than ever before.